{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T12:21:09Z","timestamp":1773058869483,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In the context of continuous emergence of SARS-CoV-2 variants of concern (VOCs), one strategy to prevent the severe outcomes of COVID-19 is developing safe and effective broad-spectrum vaccines. Here, we present preclinical studies of a RBD vaccine derived from the Gamma SARS-CoV-2 variant adjuvanted with Alum. The Gamma-adapted RBD vaccine is more immunogenic than the Ancestral RBD vaccine in terms of inducing broader neutralizing antibodies. The Gamma RBD presents more immunogenic B-cell restricted epitopes and induces a higher proportion of specific-B cells and plasmablasts than the Ancestral RBD version. The Gamma-adapted vaccine induces antigen\u00a0specific T cell immune responses and confers protection against Ancestral and Omicron BA.5 SARS-CoV-2 challenge in mice. Moreover, the\u00a0Gamma\u00a0RBD vaccine induces higher and broader neutralizing antibody activity than homologous booster vaccination in mice previously primed with different SARS-CoV-2 vaccine platforms. Our study indicates that the adjuvanted Gamma RBD vaccine is highly immunogenic and a broad-spectrum vaccine candidate.<\/jats:p>","DOI":"10.1038\/s41467-024-45180-8","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T08:02:50Z","timestamp":1706860970000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A Gamma-adapted subunit vaccine induces broadly neutralizing antibodies against SARS-CoV-2 variants and protects mice from infection"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5359-8382","authenticated-orcid":false,"given":"Lorena M.","family":"Coria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Manuel","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agostina","family":"Demaria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura A.","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayra Rios","family":"Medrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celeste Pueblas","family":"Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliana F.","family":"Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina A.","family":"Del Priore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres C.","family":"Hernando Insua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid G.","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas M.","family":"Saposnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William B.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lineia","family":"Prado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulises S.","family":"Notaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayelen N.","family":"Amweg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo U.","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Avaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Ceballos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Krum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco M.","family":"Zurvarra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna E.","family":"Sidabra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Drehe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan A.","family":"Baqu\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Li Causi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Analia V.","family":"De Nichilo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristian J.","family":"Payes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Southard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9735-0135","authenticated-orcid":false,"given":"Julio C.","family":"Vega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9048-0041","authenticated-orcid":false,"given":"Albert J.","family":"Auguste","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego E.","family":"\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0051-7435","authenticated-orcid":false,"given":"Juan M.","family":"Flo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4448-0977","authenticated-orcid":false,"given":"Karina A.","family":"Pasquevich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7122-869X","authenticated-orcid":false,"given":"Juliana","family":"Cassataro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,2]]},"reference":[{"key":"45180_CR1","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"45180_CR2","doi-asserted-by":"publisher","unstructured":"Bos, R. et al. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. npj Vaccines 5, https:\/\/doi.org\/10.1038\/s41541-020-00243-x (2020).","DOI":"10.1038\/s41541-020-00243-x"},{"key":"45180_CR3","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"45180_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99\u2013111 (2021).","journal-title":"Lancet"},{"key":"45180_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1001\/jama.2021.8565","volume":"326","author":"N Al Kaabi","year":"2021","unstructured":"Al Kaabi, N. et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults. JAMA 326, 35 (2021).","journal-title":"JAMA"},{"key":"45180_CR6","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1056\/NEJMoa2114114","volume":"385","author":"H Chemaitelly","year":"2021","unstructured":"Chemaitelly, H. et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N. Engl. J. Med. 385, e83 (2021).","journal-title":"N. Engl. J. Med."},{"key":"45180_CR7","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1056\/NEJMoa2114228","volume":"385","author":"Y Goldberg","year":"2021","unstructured":"Goldberg, Y. et al. Waning immunity after the BNT162b2 vaccine in Israel. N. Engl. J. Med. 385, e85 (2021).","journal-title":"N. Engl. J. Med."},{"key":"45180_CR8","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41586-022-05053-w","volume":"608","author":"Q Wang","year":"2022","unstructured":"Wang, Q. et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5. Nature 608, 603\u2013608 (2022).","journal-title":"Nature"},{"key":"45180_CR9","doi-asserted-by":"publisher","unstructured":"Khan, K. et al. Omicron BA.4\/BA.5 escape neutralizing immunity elicited by BA.1 infection. Nat. Commun. 13, https:\/\/doi.org\/10.1038\/s41467-022-32396-9 (2022).","DOI":"10.1038\/s41467-022-32396-9"},{"key":"45180_CR10","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.cell.2022.06.005","volume":"185","author":"A Tuekprakhon","year":"2022","unstructured":"Tuekprakhon, A. et al. Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell 185, 2422\u20132433.e2413 (2022).","journal-title":"Cell"},{"key":"45180_CR11","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s41591-022-01753-y","volume":"28","author":"HF Tseng","year":"2022","unstructured":"Tseng, H. F. et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat. Med. 28, 1063\u20131071 (2022).","journal-title":"Nat. Med."},{"key":"45180_CR12","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41586-022-04865-0","volume":"607","author":"RK Suryawanshi","year":"2022","unstructured":"Suryawanshi, R. K. et al. Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination. Nature 607, 351\u2013355 (2022).","journal-title":"Nature"},{"key":"45180_CR13","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1056\/NEJMoa2208343","volume":"387","author":"S Chalkias","year":"2022","unstructured":"Chalkias, S. et al. A bivalent omicron-containing booster vaccine against Covid-19. N. Engl. J. Med. 387, 1279\u20131291 (2022).","journal-title":"N. Engl. J. Med."},{"key":"45180_CR14","doi-asserted-by":"publisher","unstructured":"Akache, B. et al. Immunogenicity of SARS-CoV-2 spike antigens derived from Beta & Delta variants of concern. npj Vaccines 7, https:\/\/doi.org\/10.1038\/s41541-022-00540-7 (2022).","DOI":"10.1038\/s41541-022-00540-7"},{"key":"45180_CR15","doi-asserted-by":"publisher","unstructured":"Sridhar, S. et al. The potential of Beta variant containing COVID booster vaccines for chasing Omicron in 2022. Nat. Commun. 13, https:\/\/doi.org\/10.1038\/s41467-022-33549-6 (2022).","DOI":"10.1038\/s41467-022-33549-6"},{"key":"45180_CR16","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1056\/NEJMc2206711","volume":"387","author":"O Launay","year":"2022","unstructured":"Launay, O. et al. Immunogenicity and safety of beta-adjuvanted recombinant booster vaccine. N. Engl. J. Med. 387, 374\u2013376 (2022).","journal-title":"N. Engl. J. Med."},{"key":"45180_CR17","doi-asserted-by":"crossref","unstructured":"Sir Karakus, G. et al. Preclinical efficacy and safety analysis of gamma-irradiated inactivated SARS-CoV-2 vaccine candidates (Cold Spring Harbor Laboratory, 2020).","DOI":"10.1101\/2020.09.04.277426"},{"key":"45180_CR18","doi-asserted-by":"publisher","unstructured":"Turan, R. D. et al. Gamma-irradiated SARS-CoV-2 vaccine candidate, OZG-38.61.3, confers protection from SARS-CoV-2 challenge in human ACEII-transgenic mice. Sci. Rep. 11, https:\/\/doi.org\/10.1038\/s41598-021-95086-4 (2021).","DOI":"10.1038\/s41598-021-95086-4"},{"key":"45180_CR19","doi-asserted-by":"publisher","unstructured":"Khorattanakulchai, N. et al. Receptor binding domain proteins of SARS\u2010CoV\u20102 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concern. J. Med. Virol. https:\/\/doi.org\/10.1002\/jmv.27881 (2022).","DOI":"10.1002\/jmv.27881"},{"key":"45180_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40272-3","volume":"14","author":"KA Pasquevich","year":"2023","unstructured":"Pasquevich, K. A. et al. Safety and immunogenicity of a SARS-CoV-2 Gamma variant RBD-based protein adjuvanted vaccine used as booster in healthy adults. Nat. Commun. 14, 4551 (2023).","journal-title":"Nat. Commun."},{"key":"45180_CR21","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1038\/s41590-020-0778-2","volume":"21","author":"ES Winkler","year":"2020","unstructured":"Winkler, E. S. et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat. Immunol. 21, 1327\u20131335 (2020).","journal-title":"Nat. Immunol."},{"key":"45180_CR22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.cell.2020.05.027","volume":"182","author":"R-D Jiang","year":"2020","unstructured":"Jiang, R.-D. et al. Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2. Cell 182, 50\u201358.e58 (2020).","journal-title":"Cell"},{"key":"45180_CR23","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","volume":"19","author":"WT Harvey","year":"2021","unstructured":"Harvey, W. T. et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 19, 409\u2013424 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"45180_CR24","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41576-021-00408-x","volume":"22","author":"K Tao","year":"2021","unstructured":"Tao, K. et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat. Rev. Genet. 22, 757\u2013773 (2021).","journal-title":"Nat. Rev. Genet."},{"key":"45180_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00411-7","volume":"6","author":"M Brinkkemper","year":"2021","unstructured":"Brinkkemper, M. et al. A third SARS-CoV-2 spike vaccination improves neutralization of variants-of-concern. NPJ Vaccines 6, 146 (2021).","journal-title":"NPJ Vaccines"},{"key":"45180_CR26","doi-asserted-by":"publisher","unstructured":"Polyiam, K. et al. Immunodominant linear B cell epitopes in the spike and membrane proteins of SARS-CoV-2 identified by immunoinformatics prediction and immunoassay. Sci. Rep. 11, https:\/\/doi.org\/10.1038\/s41598-021-99642-w (2021).","DOI":"10.1038\/s41598-021-99642-w"},{"key":"45180_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00571-0","volume":"7","author":"Z Wang","year":"2022","unstructured":"Wang, Z. et al. A potent, broadly protective vaccine against SARS-CoV-2 variants of concern. NPJ Vaccines 7, 144 (2022).","journal-title":"NPJ Vaccines"},{"key":"45180_CR28","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1038\/s41591-022-02031-7","volume":"28","author":"S Chalkias","year":"2022","unstructured":"Chalkias, S. et al. Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2\/3 trial. Nat. Med. 28, 2388\u20132397 (2022).","journal-title":"Nat. Med."},{"key":"45180_CR29","doi-asserted-by":"publisher","first-page":"104878","DOI":"10.1016\/j.ebiom.2023.104878","volume":"98","author":"TM Nolan","year":"2023","unstructured":"Nolan, T. M. et al. Interim results from a phase I randomized, placebo-controlled trial of novel SARS-CoV-2 beta variant receptor-binding domain recombinant protein and mRNA vaccines as a 4th dose booster. EBioMedicine 98, 104878 (2023).","journal-title":"EBioMedicine"},{"key":"45180_CR30","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa2202261","volume":"386","author":"L Dai","year":"2022","unstructured":"Dai, L. et al. Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults. N. Engl. J. Med. 386, 2097\u20132111 (2022).","journal-title":"N. Engl. J. Med."},{"key":"45180_CR31","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1016\/j.cell.2022.04.029","volume":"185","author":"K Xu","year":"2022","unstructured":"Xu, K. et al. Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2. Cell 185, 2265\u20132278.e2214 (2022).","journal-title":"Cell"},{"key":"45180_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00472-2","volume":"7","author":"L Grigoryan","year":"2022","unstructured":"Grigoryan, L. et al. Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice. NPJ Vaccines 7, 55 (2022).","journal-title":"NPJ Vaccines"},{"key":"45180_CR33","doi-asserted-by":"publisher","unstructured":"Gilbert, P. B. et al. A Covid-19 Milestone Attained - A Correlate of Protection for Vaccines. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMp2211314 (2022).","DOI":"10.1056\/NEJMp2211314"},{"key":"45180_CR34","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41590-021-01122-w","volume":"23","author":"P Moss","year":"2022","unstructured":"Moss, P. The T cell immune response against SARS-CoV-2. Nat. Immunol. 23, 186\u2013193 (2022).","journal-title":"Nat. Immunol."},{"key":"45180_CR35","doi-asserted-by":"publisher","first-page":"eabl5344","DOI":"10.1126\/sciimmunol.abl5344","volume":"6","author":"G Guerrera","year":"2021","unstructured":"Guerrera, G. et al. BNT162b2 vaccination induces durable SARS-CoV-2-specific T cells with a stem cell memory phenotype. Sci. Immunol. 6, eabl5344 (2021).","journal-title":"Sci. Immunol."},{"key":"45180_CR36","doi-asserted-by":"publisher","first-page":"eabj7211","DOI":"10.1126\/scitranslmed.abj7211","volume":"13","author":"PA Swanson 2nd","year":"2021","unstructured":"Swanson, P. A. 2nd et al. AZD1222\/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T(H)1 response with a diverse TCR repertoire. Sci. Transl. Med. 13, eabj7211 (2021).","journal-title":"Sci. Transl. Med."},{"key":"45180_CR37","unstructured":"Branche, A. R. et al. SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses (Cold Spring Harbor Laboratory, 2022)."},{"key":"45180_CR38","doi-asserted-by":"publisher","first-page":"e798","DOI":"10.1016\/S2214-109X(22)00112-7","volume":"10","author":"A Jara","year":"2022","unstructured":"Jara, A. et al. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study. Lancet Glob. Health 10, e798\u2013e806 (2022).","journal-title":"Lancet Glob. Health"},{"key":"45180_CR39","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/S1473-3099(22)00427-3","volume":"22","author":"SO Rouco","year":"2022","unstructured":"Rouco, S. O. et al. Heterologous booster response after inactivated virus BBIBP-CorV vaccination in older people. Lancet Infect. Dis. 22, 1118\u20131119 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"45180_CR40","doi-asserted-by":"publisher","first-page":"844837","DOI":"10.3389\/fimmu.2022.844837","volume":"13","author":"LM Coria","year":"2022","unstructured":"Coria, L. M. et al. A novel bacterial protease inhibitor adjuvant in RBD-based COVID-19 vaccine formulations containing alum increases neutralizing antibodies, specific germinal center B cells and confers protection against SARS-CoV-2 infection in mice. Front. Immunol. 13, 844837 (2022).","journal-title":"Front. Immunol."},{"key":"45180_CR41","doi-asserted-by":"publisher","unstructured":"Corman, V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 25, https:\/\/doi.org\/10.2807\/1560-7917.ES.2020.25.3.2000045 (2020).","DOI":"10.2807\/1560-7917.ES.2020.25.3.2000045"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45180-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45180-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45180-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T12:02:54Z","timestamp":1707134574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45180-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,2]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["45180"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-45180-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.01.03.522213","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,2]]},"assertion":[{"value":"1 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.M.R., A.C.H.I., F.M.Z. are salaried employees of Fundacion Pablo Cassara. S.A.D.P., I.G.K., A.V.D.N., V.K., I.D., C.J.P., J.A.B., J.E.S., M.L.C., J.M.F. and J.C.V. are salaried employees of Laboratorio Pablo Cassara. L.M.C., J.C., K.A.P., D.E.A., A.D., C.P.C., L.A.B, L.M.S., L.P., M.R.M., E.F.C. A.J.A., W.B.S., A.N.A., U.S.N., P.U.D., M.A., A.C. and T.S. declare no competing interests relevant to this article.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"997"}}